189 results about "Antagonism" patented technology

The invention relates to a microbial agent prepared based on a new strain of bacillus velezensis, which has the function of broad-spectrum antagonism of common pathogenic bacteria of aquatic products and can effectively prevent and / or treat bacterial diseases and / or fungal diseases of aquatic organisms including crustaceans and fishes. Meanwhile, the content of nitrite and ammonia nitrogen in aquaculture water can be effectively reduced, and the usage amount and residual quantity of antibiotics and chemical drugs in aquaculture are reduced.

The invention discloses a water quality antibiotic traceability method and system based on data analysis, and the method comprises the steps: firstly constructing a water system network into a topological graph, building a physical information-graph attention network as a pollutant propagation prediction model, and enabling the model to integrate a pollutant convective diffusion partial differential equation as a physical constraint into a loss function, the physical fidelity prediction of the spatial and temporal distribution of the antibiotic concentration in the water body is realized; secondly, constructing a pollution source tracing problem as a reverse reinforcement learning task, and reversely learning a pollution source reward function capable of optimally explaining an observation result from real downstream monitoring data by adopting an antagonism reverse reinforcement learning framework and taking the propagation prediction model as a dynamic environment through antagonism training of a generator and a discriminator; and finally, generating a probability distribution diagram of the upstream candidate pollution source position according to the reward function, and performing accurate positioning in combination with a hydrodynamic constraint condition, thereby remarkably improving the accuracy, robustness and calculation efficiency of traceability.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The invention relates to the technical field of microorganisms, and particularly provides application of bacillus amyloliquefaciens BA-89 in crop growth promotion and verticillium dahliae antagonism. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36498. The strain can secrete multiple extracellular enzymes (including protease, amylase, cellulase and glucanase), has the growth promoting characteristics of producing ammonia, dissolving potassium and the like, and can tolerate high temperature and ultraviolet stress; the compound has a remarkable antagonistic effect on various plant pathogenic bacteria (such as verticillium dahliae, fusarium oxysporum and phytophthora capsici); by inoculating the strain on cotton, the plant growth can be obviously promoted, the plant height, stem diameter, root length, leaf area and biomass are improved, and meanwhile, the disease index of verticillium wilt and the colonization amount of pathogenic bacteria at the root are effectively reduced. The strain disclosed by the invention can be used as a biological fertilizer and a biological pesticide, is used for cotton cultivation and disease prevention and control, and has a wide application prospect.

The invention relates to the field of electrocardiosignal processing, and particularly discloses an electrocardiosignal classification method, device and equipment based on multi-mode electrocardiosignal characteristics and a medium thereof.The method comprises the steps that firstly, an original electrocardiosignal is preprocessed, including denoising, resampling and heartbeat segmentation; then three types of complementary features are extracted in parallel: wavelet energy features are extracted through discrete wavelet transform, deep abstract features are extracted through a neural network comprising a multi-scale residual block, a Transform encoder and a windowed global-local attention module, a knowledge graph is constructed based on clinical prior knowledge, and clinical concept features are extracted through a graph convolutional network; adaptive weighted fusion is carried out on the three types of features through a multi-modal feature fusion module; and finally, classification is performed based on the fusion features, and an unsupervised domain adaptation strategy combining antagonism domain alignment and class condition alignment is adopted in the training process. The method effectively solves the problems that a traditional method is single in feature and insufficient in cross-domain generalization ability.

The invention discloses delayed coagulation type super-early-strength quick-hardening mortar and a preparation method thereof, and relates to the technical field of building materials, a shell-core structure targeted modified early strength agent is designed, a staged dry-wet mixing technology is adopted, seabed in-situ curing is combined, cooperation of mortar delayed coagulation construction and super-early-strength development is achieved, and the construction efficiency is improved. According to the present invention, with the design of the targeted modified early strength agent, the surface delayed coagulation shell and the core early strength core structure are formed through the grafting reaction of the sodium nitrite and the hydroxyl carboxylic acid monomer, and the 15-25% accurate grafting rate control is matched, such that the antagonism problem of the traditional early strength agent and the delayed coagulation agent can be solved, and the deep sea open caisson grouting temporary support requirement can be met; in the deep sea environment, the delayed coagulation shell can guarantee a construction window of 75-105 min, the requirement for long-distance grouting of the seabed is met, deep sea high pressure can trigger the delayed coagulation shell to be broken, the core early strength core rapidly activates cement to be hydrated, and the mortar can rapidly form the requirement for rapid bearing of the open caisson temporary support with enough strength.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention discloses staphylococcus xylosus and application of the staphylococcus xylosus in antagonism of ralstonia solanacearum, and relates to the technical field of agricultural biological control, the staphylococcus xylosus CQZY-H-XJ-0002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, and the preservation number of the strain is GDMCC NO.65264. The staphylococcus xylosus CQZY-H-XJ-0002 provided by the invention is named as KQZY-H-XJ-0002. The staphylococcus xylosus CQZY-H-XJ-0002. The strain has a remarkable effect of inhibiting the growth of ralstonia solanacearum, and can effectively prevent and treat bacterial wilt and promote plant growth. The strain has the advantages of being simple in process, easy to operate, low in cost, green, safe, non-toxic and the like when being used for biological control.

The invention discloses bacillus subtilis Bs1 as well as an antagonistic substance and application thereof. According to the invention, Bs1 with antagonism on colletotrichum gloeosporioides is separated and screened for the first time, an antagonistic substance is clear as Bs1 serine-producing protease Vpr, a Bs1 bacteriostasis mechanism and biological control potential excavation are analyzed in a multi-omics manner, a peripheral colonization rule of Bs1-Rif is clear, and an indoor control strategy of the strain Bs1 on cunninghamia lanceolata anthracnose is optimized. When the strain Bs1 is applied on the day when pathogenic bacteria are inoculated, a certain prevention and treatment effect is achieved, and it is indicated that the strain Bs1 can rapidly occupy the ecological niche; the average antibacterial rate of the strain Bs1 can reach 66.69%. The biocontrol strain and theoretical basis are provided for prevention and control of Chinese fir diseases, the application of biological prevention and control in forestry is promoted, the interaction mechanism of biocontrol bacteria and pathogenic bacteria can be deeply understood, and the sustainable development requirement of modern forestry is met.

The invention discloses Erwinia phyllostachys ZX-13 and application thereof in antagonism of epidemic disease pathogenic bacteria of Eupin, and belongs to the technical field of microorganisms. The invention discloses a Erwinia phyllostachys ZX-13, and the preservation number of the Erwinia phyllostachys ZX-13 is GDMCC No: 66800. The Erwinia phyllostachys ZX-13 disclosed by the invention can be used for preventing and treating the epidemic disease of the elaphus japonicus caused by the cryptophyton pseudophyllanthus of the elaphus japonicus; the Erwinia rhizosphere ZX-13 is a biological control potential strain with good antagonism effect, high control effect and good environmental safety, and has good development and application prospects.

The invention provides an anti-PD-1 antibody, a CAR-T cell, and a preparation method and application thereof. The anti-PD-1 antibody comprises LCDR-1-3 as shown in SEQ ID NO: 1-3 and HCDR-1-3 as shown in SEQ ID NO: 4-6, respectively. The CAR-T cell expresses a novel element for efficiently blocking the PD-1, and the element is a single-chain antibody for targeting the PD-1 in a cell membrane anchoring manner. And the chimeric antigen receptor and the cell membrane anchored anti-PD-1 scFv are connected by a 2A cleavage protein. The membrane anchor type anti-PD-1 scFv expressed by the CAR-T cell can almost completely block the expression of PD-1 on the surface of a T cell membrane, and further block a signal channel combined with PD-1 / PD-L1, so that the capability of T cell depletion caused by antagonism tumor of the CAR-T cell is enhanced, and the purpose of enhancing the anti-tumor effect of the CAR-T cell is achieved.

Compositions comprising anti-PD-1 antibodies and related methods for treating cancer and other disorders responsive to PD-1 antagonism are provided.SOLUTION: A composition comprising an oxidized variant of an anti-PD-1 antibody, wherein the oxidized variant comprises a heavy chain amino acid sequence comprising CDRH1-3 each consisting of a specific amino acid sequence and a light chain amino acid sequence comprising CDRL1-3 each consisting of a specific amino acid sequence; wherein the composition comprises no more than 65% oxidized variants.SELECTED DRAWING: None

The invention discloses bacillus subtilis, a complex microbial inoculant and application of the complex microbial inoculant to degradation of mycotoxin, and belongs to the field of microorganisms and fermentation engineering. According to the invention, a strain of bacillus subtilis BLYC-1937 with the activity of degrading mycotoxin is obtained through screening, and the bacillus subtilis BLYC-1937 has a good degradation effect on pollution of single toxin of T-2 toxin, vomitoxin, fumonisins B1, aflatoxin B1 and ochratoxin A or combined pollution of multiple toxins; the strain has good antagonism on fusarium oxysporum capable of producing T-2 toxin and aspergillus ochraceus capable of producing ochratoxin A, and pollution of T-2 toxin and ochratoxin A can be reduced from the source.

The invention relates to a drug combination data processing method and system based on organ adverse reactions, and the method comprises the steps: carrying out the graph neural network fusion of multi-source patient medical data, and carrying out the cross-scale integration of organ function parameters, metabolic characteristics and hemodynamic data; extracting a core biomarker by utilizing principal component analysis and organ specificity screening, and generating a feature vector representing organ reaction; constructing a nonlinear drug interaction model by combining a dose-time sequence and in-vitro experimental data, and quantifying the strength of synergy and antagonism; gene expression profiles, pathological states and lifestyle data are introduced for triple dynamic calibration, and individualized adverse reaction probability optimization is achieved; monte Carlo sampling is adopted to simulate an organ toxicity scene, and intelligent classification decision is performed on a high-risk combination scheme based on a supervision rule base. The method breaks through the limitation of data islands, static evaluation and individualization deficiency in the traditional technology, and significantly improves the prediction precision and clinical applicability of the drug combination safety.

The invention provides a composition with an effect of improving iron-deficiency anemia as well as a preparation method and application of the composition, and belongs to the technical field of pharmaceutical compositions. The composition with the effect of improving iron-deficiency anemia, provided by the invention, is prepared from the following raw materials in parts by weight: 15 to 20 parts of radix astragali seu hedysari extract, 5 to 10 parts of fructus jujubae extract, 2 to 5 parts of radix paeoniae alba extract, 4 to 8 parts of radix angelicae sinensis extract and 8 to 16 parts of ethylenediaminetetraacetic acid ferric sodium salt. The defect of single effect in the prior art is broken through, the synergistic effect of the four effects of improving iron-deficiency anemia, helping sleep, improving acne and protecting gastric mucosa is achieved through scientific compatibility, the conditioning requirements of crowds with multiple diseases can be met without taking multiple products, the eating burden is reduced, meanwhile, the antagonistic effect among different product components is avoided, and the health-care product is suitable for being popularized and applied. The overall conditioning effect can be improved.

Methods of improving nutrition in subjects, including individuals who have undergone gastrointestinal surgery, by avexitide therapy are disclosed. Avexitide may be administered subcutaneously or intravenously as a part of a liquid pharmaceutical formulation. Avexitide therapy may improve weight and / or nutritional intake / status in subjects.

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.

The present invention provides a solid dispersion comprising a compound represented by a general formula (I) or (II), or a pharmacologically acceptable salt thereof: or

The present invention relates to a pharmaceutical composition for preventing or treating respiratory disease, particularly, inflammatory respiratory disease, the pharmaceutical composition including a compound having a P2X4 receptor antagonistic action or a pharmaceutically acceptable salt of the compound as an active ingredient.

The invention discloses low-caffeine nerve stimulation tea wine and a preparation method thereof, the low-caffeine nerve stimulation tea wine is prepared by blending eucommia wood aged tea wine, cherry wood aged tea wine and cherry wood / Hainan dalbergia odorifera wood aged tea wine with different baking degrees, and the mass ratio of geniposidic acid to salidroside to formononetin in the wine body is (2-30): (1-15): 1. The mass ratio of the genkwanin to the alpinia japonica to the sesamol is (0.5-8): (0.15-6): 1, the mass ratio of the isoliquiritigenin to the vitexin to the syringaldehyde is 1: (0.15-5): (4-18), and the total content of the geniposidic acid, the salidroside, the formononetin, the genkwanin, the alpinia japonica, the sesamol, the isoliquiritigenin, the vitexin and the syringaldehyde in the wine is 40-250 mg / 100 mL. By combining and matching the functional components in the wood and the proportion of the functional components, the antagonistic effect on caffeine nerve stimulation in the tea wine is achieved.

A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

The invention provides an application of a quinoline derivative as shown in a formula (1) in preparation of drugs for treating acute lung injury and resisting inflammation. It is found for the first time that the quinoline derivative has the function of a P2Y6R antagonist, has an obvious antagonistic effect on P2Y6R-related inflammation and can be used for preparing P2Y6R-related anti-inflammatory drugs.

The invention discloses a method for preventing and treating sclerotinia rot of colza by antagonistic trichoderma strains, and relates to the technical field of agricultural disease prevention and control, and the method comprises the following specific steps: S100, strain screening and mutagenesis: separating trichoderma strains from rhizosphere soil of colza in different environments, primarily screening strains with antagonistic action on sclerotinia sclerotiorum by a plate confrontation method, and carrying out mutagenesis on the strains with antagonistic action on sclerotinia sclerotiorum; carrying out chemical mutagenesis treatment on the primarily screened strains, carrying out confrontation culture on the primarily screened strains and sclerotinia sclerotiorum again, screening out high-yield antagonistic substances with larger inhibition zones and mutant strains with strong stress resistance, and culturing to obtain trichoderma fermentation liquor; by obtaining the trichoderma strains which can keep efficient antagonism and strong stress resistance under different environmental conditions, the stability of the trichoderma strains on disease control is enhanced, so that the rape can effectively resist invasion of sclerotiniose under different environmental conditions in the growth process, and the disease resistance of the rape is improved. And antagonistic active substances are extracted to prepare a biological fertilizer carrier, and the biological fertilizer carrier is applied to the planting process of oilseed rape, so that the growth and reproduction of sclerotinia sclerotiorum are effectively inhibited.

The invention belongs to the technical field of bioengineering, and discloses a UBXN10 active polypeptide, a carrier thereof and application of the UBXN10 active polypeptide in anti-cancer drugs. The amino acid sequence of the UBXN10 active polypeptide is as shown in SEQ ID NO: 1, and the nucleotide sequence for coding the UBXN10 active polypeptide is as shown in SEQ ID NO: 2. According to the invention, a plurality of functional means are utilized to analyze the transcriptional activity of cancer promoting beta-catenin in colorectal cancer cells and the antagonism of cancer cell proliferation and stem cell nature. The cell biology level proves that the UBXN10 active polypeptide has the potential of antagonizing beta-catenin mediated proliferation and stem cell gene expression and inhibiting colorectal cancer cell proliferation and stem cell property.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

The invention relates to application of azole drugs in preparation of antifungal drugs, and belongs to the technical field of research and development of antifungal drugs. According to the application of the glycyrrhetinic acid combined with the azoles in preparation of the antifungal drugs, the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole shows a good synergistic effect or antagonistic effect on aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans, and the application of the glycyrrhetinic acid combined with the itraconazole, the voriconazole and the posaconazole in preparation of the antifungal drugs is disclosed. And a research and development direction is provided for preparing medicines for resisting aspergillus, ectobottle dermatitis, candida and cryptococcus neoformans.

This invention provides a pharmaceutical product for the prevention and / or treatment of pain, particularly neuropathic pain associated with multiple sclerosis, containing compounds with P2X4 receptor antagonism, such as compounds represented by general formula (IH), or their salts, or their hydrates or solvates, as active ingredients.

A Toll-like receptor (TLR) is an indispensable component of an innate immune system and plays a key role in identifying and coping with microbial pathogens. TLR7, TLR8, and TLR9 are located in the endosome-lysosome compartment within the cell and then exclusively used to detect nucleic acids of a microorganism after the microorganism is swallowed and reaches the endosome compartment. The biological importance of the TLR agonists lies in that they can be used as powerful tools for studying innate immune responses, developing vaccines and potential therapeutic applications. In addition, TLR agonists have been explored for use as immunotherapy, while these TLR antagonists can be used as new pathogenic nodes in the context of different autoimmune diseases. Therefore, the agonists and antagonists of the endosomal TLR have therapeutic significance in different clinical backgrounds. The previous study on 8-oxo adenines shows that the C-6-site-NH2 group is extremely important for the recognition of agonistic active sites and the subsequent induction of interferon (IFN). The present invention explores the ability of a hydrogen-substituted 8-oxopurine derivative that does not contain an essential C-6 amine group. The C-6 amino group in the 8-oxopurine derivative is substituted by hydrogen (H), providing an exciting opinion for regulating the endosome TLRs (Toll-Like Receptors). The ability of 8-oxopurine derivatives to modulate the endosomal TLR has been reported, which derivatives are related / interrelated to various substitutions at N-7, N-9 and C-2, all derivatives containing hydrogen at C-6. Structure 1

The invention discloses an oral patch platform based on multi-mechanism synergy and micro-matrix controlled release and a preparation method thereof. The patch comprises core nutrients (such as iron, calcium, folic acid and zinc) and a synergistic nutrient system (such as vitamin C, vitamin D, vitamin B12 and copper), and the release kinetics of different nutrients are accurately regulated and controlled through a physically separated multi-cavity structure (such as a double-semicircular laminated sheet) or a unique hydrophilic-hydrophobic micro-matrix component design; the effects of synergistically promoting absorption, assisting metabolism or preventing antagonism are achieved. According to the invention, the first-pass effect of the liver is avoided through oral mucosa absorption, and the composition can be attached to multiple sites in the oral cavity, so that the absorption efficiency, the bioavailability and the supplement safety of target nutrients are remarkably improved, and the composition is suitable for developing a series of nutritional supplement products or medicine products.